Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06618183 · ClinicalTrials.gov registry record
Drug Screening System Method Comparison
A clinical trial of Reagent Kits, Diagnostic, sponsored by Intelligent Bio Solutions.
- Recruiting
- Registry status
- 135
- Enrollment target
- 3
- Study locations
NCT06618183: Recruiting study of Reagent Kits, Diagnostic, sponsored by Intelligent Bio Solutions.
NCT06618183 is a study of Reagent Kits, Diagnostic that is actively recruiting participants, run by Intelligent Bio Solutions. The registered enrollment target is 135 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06618183, a study of Reagent Kits, Diagnostic, is actively recruiting participants, sponsored by Intelligent Bio Solutions.
- RECRUITING
- Registry status
- 135 participants
- Enrollment target
- 3
- Study locations
Study Summary
Prospective, open-label, single-dose, randomized, multi-site performance evaluation of the accuracy and usability Intelligent Fingerprinting Drug Screening System in the hands of intended users: "operators" and "donors."
Primary Outcome
Comparison of the sensitivity, specificity, and accuracy of the Intelligent Fingerprinting Drug Screening System (qualitative lateral-flow immunoassay) to the validated confirmatory LC-MS/MS technique
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Fingerprint sweat drug screen
- DIAGNOSTIC_TEST Fingerprint sweat laboratory analysis
Study Locations (3)
New Jersey
- CenExel HRI - Berlin
- CenExel HRI - Marlton
Georgia
- CenExel iResearch - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2024-12-31 |
What NCT06618183 shows while recruiting
NCT06618183 is an observational study that tracks outcomes without assigning an intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Reagent Kits, Diagnostic appearing as the primary indexed condition, and to 2 interventions - of which Fingerprint sweat drug screen is the first listed.
NCT06618183 reports a single indexed study location in New Jersey, Georgia.
Frequently Asked Questions
What is clinical trial NCT06618183 about?
NCT06618183 is a clinical study titled "Drug Screening System Method Comparison". Prospective, open-label, single-dose, randomized, multi-site performance evaluation of the accuracy and usability Intelligent Fingerprinting Drug Screening System in the hands of intended users: "operators" and "donors."
What is the current status of trial NCT06618183?
This trial is currently recruiting. The enrollment target is 135 participants. The study started on 2024-08-26. Estimated completion is 2024-12-31.
What conditions does trial NCT06618183 study?
This clinical trial studies the following conditions: Reagent Kits, Diagnostic.
What interventions are being tested in trial NCT06618183?
The interventions under investigation include: Fingerprint sweat drug screen (DIAGNOSTIC_TEST), Fingerprint sweat laboratory analysis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06618183?
This trial is sponsored by Intelligent Bio Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06618183 being conducted?
This trial has 3 study locations across Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI